Page 2,158«..1020..2,1572,1582,1592,160..2,1702,180..»

Stem cell findings may offer answers for some bladder defects, disease

Posted: March 22, 2014 at 12:49 am

For the first time, scientists have succeeded in coaxing laboratory cultures of human stem cells to develop into the specialized, unique cells needed to repair a patient's defective or diseased bladder.

The breakthrough, developed at the UC Davis Institute for Regenerative Cures and published today in the scientific journal Stem Cells Translational Medicine, is significant because it provides a pathway to regenerate replacement bladder tissue for patients whose bladders are too small or do not function properly, such as children with spina bifida and adults with spinal cord injuries or bladder cancer.

"Our goal is to use human stem cells to regenerate tissue in the lab that can be transplanted into patients to augment or replace their malfunctioning bladders," said Eric Kurzrock, professor and chief of the division of pediatric urologic surgery at UC Davis Children's Hospital and lead scientist of the study, which is titled "Induction of Human Embryonic and Induced Pluripotent Stem Cells into Urothelium."

To develop the bladder cells, Kurzrock and his UC Davis colleagues investigated two categories of human stem cells. In their key experiments, they used induced pluripotent stem cells (iPS cells), which were derived from lab cultures of human skin cells and umbilical blood cells that had been genetically reprogrammed to convert to an embryonic stem cell-like state.

If additional research demonstrates that grafts of bladder tissue grown from human stem cells will be safe and effective for patient care, Kurzrock said that the source of the grafts would be iPS cells derived from a patient's own skin or umbilical cord blood cells. This type of tissue would be optimal, he said, because it lowers the risk of immunological rejection that typifies most transplants.

In their investigation, Kurzrock and his colleagues developed a protocol to prod the pluripotent cells into becoming bladder cells. Their procedure was efficient and, most importantly, the cells proliferated over a long period of time -- a critical element in any tissue engineering application.

"What's exciting about this discovery is that it also opens up an array of opportunities using pluripotent cells," said Jan Nolta, professor and director of the UC Davis Stem Cell program and a co-author on the new study. "When we can reliably direct and differentiate pluripotent stem cells, we have more options to develop new and effective regenerative medicine therapies. The protocols we used to create bladder tissue also provide insight into other types of tissue regeneration."

UC Davis researchers first used human embryonic stem cells obtained from the National Institutes of Health's repository of human stem cells. Embryonic stem cells can become any cell type in the body (i.e., they are pluripotent), and the team successfully coaxed these embryonic stem cells into bladder cells. They then used the same protocol to coax iPS cells made from skin and umbilical cord blood into bladder cells, called urothelium, that line the inside of the bladder. The cells expressed a very unique protein and marker of bladder cells called uroplakin, which makes the bladder impermeable to toxins in the urine.

The UC Davis researchers adjusted the culture system in which the stem cells were developing to encourage the cells to proliferate, differentiate and express the bladder protein without depending upon signals from other human cells, said Kurzrock. In future research, Kurzrock and his colleagues plan to modify the laboratory cultures so that they will not need animal and human products, which will allow use of the cells in patients.

Kurzrock's primary focus as a physician is with children suffering from spina bifida and other pediatric congenital disorders. Currently, when he surgically reconstructs a child's defective bladder, he must use a segment of their own intestine. Because the function of intestine, which absorbs food, is almost the opposite of bladder, bladder reconstruction with intestinal tissue may lead to serious complications, including urinary stone formation, electrolyte abnormalities and cancer. Developing a stem cell alternative not only will be less invasive, but should prove to be more effective, too, he said.

Read more from the original source:
Stem cell findings may offer answers for some bladder defects, disease

Posted in Stem Cells | Comments Off on Stem cell findings may offer answers for some bladder defects, disease

Stem cell findings may offer answers for some bladder defects and disease

Posted: March 22, 2014 at 12:49 am

PUBLIC RELEASE DATE:

21-Mar-2014

Contact: Charles Casey charles.casey@ucdmc.ucdavis.edu 916-734-9048 University of California - Davis Health System

(SACRAMENTO, Calif.) For the first time, scientists have succeeded in coaxing laboratory cultures of human stem cells to develop into the specialized, unique cells needed to repair a patient's defective or diseased bladder.

The breakthrough, developed at the UC Davis Institute for Regenerative Cures and published today in the scientific journal Stem Cells Translational Medicine, is significant because it provides a pathway to regenerate replacement bladder tissue for patients whose bladders are too small or do not function properly, such as children with spina bifida and adults with spinal cord injuries or bladder cancer.

"Our goal is to use human stem cells to regenerate tissue in the lab that can be transplanted into patients to augment or replace their malfunctioning bladders," said Eric Kurzrock, professor and chief of the division of pediatric urologic surgery at UC Davis Children's Hospital and lead scientist of the study, which is titled "Induction of Human Embryonic and Induced Pluripotent Stem Cells into Urothelium."

To develop the bladder cells, Kurzrock and his UC Davis colleagues investigated two categories of human stem cells. In their key experiments, they used induced pluripotent stem cells (iPS cells), which were derived from lab cultures of human skin cells and umbilical blood cells that had been genetically reprogrammed to convert to an embryonic stem cell-like state.

If additional research demonstrates that grafts of bladder tissue grown from human stem cells will be safe and effective for patient care, Kurzrock said that the source of the grafts would be iPS cells derived from a patient's own skin or umbilical cord blood cells. This type of tissue would be optimal, he said, because it lowers the risk of immunological rejection that typifies most transplants.

In their investigation, Kurzrock and his colleagues developed a protocol to prod the pluripotent cells into becoming bladder cells. Their procedure was efficient and, most importantly, the cells proliferated over a long period of time a critical element in any tissue engineering application.

"What's exciting about this discovery is that it also opens up an array of opportunities using pluripotent cells," said Jan Nolta, professor and director of the UC Davis Stem Cell program and a co-author on the new study. "When we can reliably direct and differentiate pluripotent stem cells, we have more options to develop new and effective regenerative medicine therapies. The protocols we used to create bladder tissue also provide insight into other types of tissue regeneration."

See the rest here:
Stem cell findings may offer answers for some bladder defects and disease

Posted in Stem Cells | Comments Off on Stem cell findings may offer answers for some bladder defects and disease

Regenerative Medicine – Video

Posted: March 22, 2014 at 12:49 am


Regenerative Medicine
Regenerative Medicine is a same-day, non-surgical adult stem cell procedure for treating common injuries and degenerative joint conditions. Hear how one pati...

By: ProMedica

Read more:
Regenerative Medicine - Video

Posted in Regenerative Medicine | Comments Off on Regenerative Medicine – Video

BIO Announces New Health Focused Specialty Forums at the 2014 BIO International Convention in …

Posted: March 22, 2014 at 12:48 am

March 20, 2014 - Orphan Disease Forum, Regenerative Medicine Forum, Personalized Medicineand Diagnostics Forum, and Vaccines& Immunotherapeutics Forum will highlight pressing health issues at 2014 BIO International Convention, which will take placeJune 2326 in in San Diego, CA. According to BIO International Convention President Scott Whitaker,these "highly-focused and interactive forums" will provide educational content and provide dedicated time for collaboration and networking with industry peers. Biotechnology Industry Organization 1201 Maryland Ave., SW, Ste. 900 Washington, DC, 20024 USA Press release date: March 13, 2014

New Forums to focus on orphan diseases, personalized medicine, regenerative medicine and vaccines

2014 BIO International Convention WASHINGTON--The Biotechnology Industry Organization (BIO) today announced Specialty Forums that will highlight the most pressing health issues facing our industry at the 2014 BIO International Convention in San Diego . The Convention, June 23-26, attracts the biggest names in biotech, offers key networking and partnering opportunities and provides insights and inspiration on major trends affecting the industry. New at BIO 2014, programming will take place for three full days from Tuesday, June 24th through Thursday, June 26th.

These new, highly-focused and interactive forums will not only provide great educational content, but will culminate in a unique and dedicated time for collaboration and networking with your industry peers. We are excited that these new session formats will offer an improved three-day Convention educational experience.

Today, the biotech industry is faced with more promise and greater challenges than we have seen in years. As a result of these challenges, the Convention has designed a series of new Specialty Forums which will offer in-depth conversations and unique perspectives from top business leaders and scientists working to develop the next generation of miracle medicines, said Scott Whitaker, President of the BIO International Convention. These new, highly-focused and interactive forums will not only provide great educational content, but will culminate in a unique and dedicated time for collaboration and networking with your industry peers. We are excited that these new session formats will offer an improved three-day Convention educational experience.

Sponsored by CSL Behring and Genzyme, a Sanofi company, the Orphan Disease Forum, June 24, will provide a unique perspective on the international orphan drug marketplace, new and emerging funding models, the vital role of patient advocacy organizations and the scientific and regulatory considerations for orphan drug development.

The Regenerative Medicine Forum, June 25, will delve into the ways stem cell science and regenerative medicine are impacting the biotechnology and pharmaceutical industries as well as the reasons why the reimbursement community has started to watch the developments in this rapidly emerging field. New for BIO 2014, the California Institute for Regenerative Medicine will sponsor this forum.

Spanning June 25-26, the Personalized Medicine & Diagnostics Forum and the Vaccines & Immunotherapeutics Forum will hear from business thought leaders from Ernst & Young, Roche and Foundation Medicine as well as key partners such as the Bill and Melinda Gates Foundation and the European Commission.

Advance media registration is now available for qualified reporters working full time for print, broadcast and web publications with valid press credentials. To register, please visit here.

For registration, schedule at a glance and exhibitor information, visit 2014 BIO International Convention. Once registered, search all attendees, sessions, events, exhibitors, partnering companies and more with myBIO.

Go here to see the original:
BIO Announces New Health Focused Specialty Forums at the 2014 BIO International Convention in ...

Posted in Regenerative Medicine | Comments Off on BIO Announces New Health Focused Specialty Forums at the 2014 BIO International Convention in …

Stem Cell Training, Inc. and Bioheart, Inc. Complete First U.S.-based Stem Cell Training Course

Posted: March 22, 2014 at 12:44 am

Miami (PRWEB) March 21, 2014

Stem Cell Training, Inc., a division of the Global Stem Cells Group, and Bioheart, Inc. have announced the successful completion of their first joint stem cell training course held in the U.S.

Titled Adipose Derived Harvesting, Isolation and Re-integration Training Course, for the advancement of stem cell procedures, the two companies hosted 14 students in Miami for the training, conducted by Bioheart CSO Kristin Comella.

The two-day, hands-on intensive training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells derived from adipose (fat) tissue and bone marrow. The objective of the training is to bridge the gap between bench science in the laboratory and the doctors office by teaching effective in office regenerative medicine techniques.

Comella, Chief Scientific Officer for Bioheart, has more than 15 years experience in cell culturing and developing stem cell therapies for degenerative diseases, and experience in corporate entities, with expertise in regenerative medicine, training and education, research, product development and senior management.

The two companies will conduct 12 stem cell training courses in the U.S. during 2014. For more information, visit the Stem Cell Training, Inc. website, email info(at)stemcelltraining(dot)net, or call 305-224-1858.

About Stem Cell Training, Inc.:

Stem Cell Training, Inc. is a multi-dimensional company offering coursework and training in 35 cities worldwide. Coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.

The companys training courses are designed to make the best use of stem cell technology available to treat various diseases in a manner that is accessible to everyone. Stem Cell Training, Inc.s mission is to introduce the promising world of cellular medicine to everyone who can benefit from its application, and to provide high quality, effective and efficient training that complies with the highest medical standards to physicians worldwide.

About the Global Stem Cells Group:

Go here to see the original:
Stem Cell Training, Inc. and Bioheart, Inc. Complete First U.S.-based Stem Cell Training Course

Posted in Cell Medicine | Comments Off on Stem Cell Training, Inc. and Bioheart, Inc. Complete First U.S.-based Stem Cell Training Course

Should stem cell therapy be used in DLCBL? – Video

Posted: March 22, 2014 at 12:43 am


Should stem cell therapy be used in DLCBL?
Response based on the findings of the case study presented by Prof. Marek Trnn Transcript: The question to consider is whether a stem cell transplant is su...

By: Emmet Dunne

Read the original here:
Should stem cell therapy be used in DLCBL? - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Should stem cell therapy be used in DLCBL? – Video

Stem Cells Blues No.1 – Video

Posted: March 21, 2014 at 4:50 pm


Stem Cells Blues No.1

By: gnakamura gkose

The rest is here:
Stem Cells Blues No.1 - Video

Posted in Stem Cell Videos | Comments Off on Stem Cells Blues No.1 – Video

Hip conditions treated with Stem Cell Therapy and PRP – Video

Posted: March 21, 2014 at 6:44 am


Hip conditions treated with Stem Cell Therapy and PRP
In this video, Ross Hauser, MD discusses some of the most common hip conditions that we treat at Caring Medical with Stem Cell Therapy and Platelet Rich Plas...

By: Caring Medical and Rehabilitation Services

Read more:
Hip conditions treated with Stem Cell Therapy and PRP - Video

Posted in Stem Cell Therapy | Comments Off on Hip conditions treated with Stem Cell Therapy and PRP – Video

USF study finds stem cell combination therapy improves traumatic brain injury outcomes

Posted: March 21, 2014 at 6:43 am

PUBLIC RELEASE DATE:

20-Mar-2014

Contact: Anne DeLotto Baier abaier@health.usf.edu 813-974-3303 University of South Florida (USF Innovation)

Tampa, FL (Mar. 20, 2014) Traumatic brain injuries (TBI), sustained by close to 2 million Americans annually, including military personnel, are debilitating and devastating for patients and their families. Regardless of severity, those with TBI can suffer a range of motor, behavioral, intellectual and cognitive disabilities over the short or long term. Sadly, clinical treatments for TBI are few and largely ineffective.

In an effort to find an effective therapy, neuroscientists at the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery in the USF Health Morsani College of Medicine, University of South Florida, have conducted several preclinical studies aimed at finding combination therapies to improve TBI outcomes.

In their study of several different therapiesalone and in combinationapplied to laboratory rats modeled with TBI, USF researchers found that a combination of human umbilical cord blood cells (hUBCs) and granulocyte colony stimulating factor (G-CSF), a growth factor, was more therapeutic than either administered alone, or each with saline, or saline alone.

The study appeared in a recent issue of PLoS ONE.

"Chronic TBI is typically associated with major secondary molecular injuries, including chronic neuroinflammation, which not only contribute to the death of neuronal cells in the central nervous system, but also impede any natural repair mechanism," said study lead author Cesar V. Borlongan, PhD, professor of neurosurgery and director of USF's Center of Excellence for Aging and Brain Repair. "In our study, we used hUBCs and G-CSF alone and in combination. In previous studies, hUBCs have been shown to suppress inflammation, and G-CSF is currently being investigated as a potential therapeutic agent for patients with stroke or Alzheimer's disease."

Their stand-alone effects have a therapeutic potential for TBI, based on results from previous studies. For example, G-CSF has shown an ability to mobilize stem cells from bone marrow and then infiltrate injured tissues, promoting self-repair of neural cells, while hUBCs have been shown to suppress inflammation and promote cell growth.

The involvement of the immune system in the central nervous system to either stimulate repair or enhance molecular damage has been recognized as key to the progression of many neurological disorders, including TBI, as well as in neurodegenerative diseases such as Parkinson's disease, multiple sclerosis and some autoimmune diseases, the researchers report. Increased expression of MHCII positive cellscell members that secrete a family of molecules mediating interactions between the immune system's white blood cellshas been directly linked to neurodegeneration and cognitive decline in TBI.

Visit link:
USF study finds stem cell combination therapy improves traumatic brain injury outcomes

Posted in Stem Cell Therapy | Comments Off on USF study finds stem cell combination therapy improves traumatic brain injury outcomes

A*STAR scientists create stem cells from a drop of blood

Posted: March 21, 2014 at 6:43 am

PUBLIC RELEASE DATE:

20-Mar-2014

Contact: Tan Yun Yun tan_yun_yun@a-star.edu.sg 656-826-6273 Biomedical Sciences Institutes (BMSI)

1. Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have developed a method to generate human induced pluripotent stem cells (hiPSCs) from a single drop of finger-pricked blood. The method also enables donors to collect their own blood samples, which they can then send to a laboratory for further processing. The easy access to blood samples using the new technique could potentially boost the recruitment of greater numbers and diversities of donors, and could lead to the establishment of large-scale hiPSC banks.

2. By genetic reprogramming, matured human cells, usually blood cells, can be transformed into hiPSCs. As hiPSCs exhibit properties remarkably similar to human embryonic stem cells, they are invaluable resources for basic research, drug discovery and cell therapy. In countries like Japan, USA and UK , a number of hiPSC bank initiatives have sprung up to make hiPSCs available for stem cell research and medical studies.

3. Current sample collection for reprogramming into hiPSCs include invasive measures such as collecting cells from the bone marrow or skin, which may put off many potential donors. Although hiPSCs may also be generated from blood cells, large quantities of blood are usually required. In the paper published online on the Stem Cell Translational Medicine journal, scientists at IMCB showed for the first time that single-drop volumes of blood are sufficient for reprogramming into hiPSCs. The finger-prick technique is the world's first to use only a drop of finger-pricked blood to yield hiPSCs with high efficiency. A patent has been filed for the innovation.

4. The accessibility of the new technique is further enhanced with a DIY sample collection approach. Donors may collect their own finger-pricked blood, which they can then store and send it to a laboratory for reprogramming. The blood sample remains stable for 48 hours and can be expanded for 12 days in culture, which therefore extends the finger-prick technique to a wide range of geographical regions for recruitment of donors with varied ethnicities, genotypes and diseases.

5. By integrating it with the hiPSC bank initiatives, the finger-prick technique paves the way for establishing diverse and fully characterised hiPSC banking for stem cell research. The potential access to a wide range of hiPSCs could also replace the use of embryonic stem cells, which are less accessible. It could also facilitate the set-up of a small hiPSC bank in Singapore to study targeted local diseases.

6. Dr Loh Yuin Han Jonathan, Principal Investigator at IMCB and lead scientist for the finger-prick hiPSC technique, said, "It all began when we wondered if we could reduce the volume of blood used for reprogramming. We then tested if donors could collect their own blood sample in a normal room environment and store it. Our finger-prick technique, in fact, utilised less than a drop of finger-pricked blood. The remaining blood could even be used for DNA sequencing and other blood tests."

7. Dr Stuart Alexander Cook, Senior Consultant at the National Heart Centre Singapore and co-author of the paper, said "We were able to differentiate the hiPSCs reprogrammed from Jonathan's finger-prick technique, into functional heart cells. This is a well-designed, applicable technique that can unlock unrealized potential of biobanks around the world for hiPSC studies at a scale that was previously not possible."

Excerpt from:
A*STAR scientists create stem cells from a drop of blood

Posted in Stem Cell Therapy | Comments Off on A*STAR scientists create stem cells from a drop of blood

Page 2,158«..1020..2,1572,1582,1592,160..2,1702,180..»